PE20010627A1 - Composiciones que tienen estabilidad mejorada - Google Patents
Composiciones que tienen estabilidad mejoradaInfo
- Publication number
- PE20010627A1 PE20010627A1 PE2000001034A PE0010342000A PE20010627A1 PE 20010627 A1 PE20010627 A1 PE 20010627A1 PE 2000001034 A PE2000001034 A PE 2000001034A PE 0010342000 A PE0010342000 A PE 0010342000A PE 20010627 A1 PE20010627 A1 PE 20010627A1
- Authority
- PE
- Peru
- Prior art keywords
- active
- improved stability
- agent
- active agent
- ionized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION LIQUIDA ORAL QUE TIENE ESTABILIDAD MEJORADA QUE COMPRENDE a)UN AGENTE ACTIVO DE PESO MOLECULAR INFERIOR A 500 g/MOL, COMO ANTITUSIVOS, ANTIHISTAMINICOS, DESCONGESTIONANTES, EXPECTORANTES, MUCOLITICOS, ANALGESICOS, AGENTES ANTIPIRETICOS, SEDANTES; b)UN DISOLVENTE ANHIDRO HIDROFILO, MISCIBLE EN AGUA COMO PROPILENGLICOL, ETANOL, CARBONATO DE PROPILENO, ENTRE OTROS; c)DE 0,005% A 1% DE UN AGENTE QUELANTE COMO SALES DISODICAS, CALCICAS DEL ACIDO ETILENDIAMINOACETICO, EDTA TETRASODICA, ACIDO CITRICO, ENTRE OTROS, QUE SE ENCUENTRA EN UNA FASE DIFERENTE DE LA FASE DEL ACTIVO, QUE TIENE UNA ESTABILIDAD MEJORADA; d)DE 0,0050% A 1% DE UN AGENTE DE REDUCCION COMO SALES BISULFITO, SODICAS, POTASICAS, DITIOERITRIOL, TIOUREA, ENTRE OTROS CON UN POTENCIAL DE ELECTRODO E° SUPERIOR A -0,119V, EL AGENTE QUELANTE Y DE REDUCCION SON ACTIVOS A UN pH DE 5 A 12, EN COMPOSICIONES DISOLVENTES ACUOSAS Y NO ACUOSAS; EL AGENTE ACTIVO EN SU FORMA NO IONIZADA TIENE UNA SOLUBILIDAD A TEMPERATURA AMBIENTE IGUAL O SUPERIOR A 0,75%; EL AGENTE ACTIVO ES CAPAZ DE SER IONIZADO EN DISOLVENTE ACUOSO, TIENE UN COEFICIENTE DE PARTICION DE OCTANOL:AGUA CUANDO ESTA EN LA FORMA NO IONIZADA DE 100. LA COMPOSICION PUEDE SER UTIL PARA TRATAR ENFERMEDADES RESPIRATORIAS UTILIZANDO NO MAS DE 3ml
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15654099P | 1999-09-29 | 1999-09-29 | |
US09/467,333 US20020082307A1 (en) | 1999-01-11 | 1999-12-20 | Compositions having improved stability |
US17928900P | 2000-01-31 | 2000-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20010627A1 true PE20010627A1 (es) | 2001-06-14 |
Family
ID=27387886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000001034A PE20010627A1 (es) | 1999-09-29 | 2000-09-29 | Composiciones que tienen estabilidad mejorada |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1216044A1 (es) |
JP (1) | JP2003510279A (es) |
CN (1) | CN1211085C (es) |
AU (1) | AU770376B2 (es) |
BR (1) | BR0014441A (es) |
CA (1) | CA2385990A1 (es) |
CO (1) | CO5210868A1 (es) |
CZ (1) | CZ2002947A3 (es) |
HU (1) | HUP0202797A3 (es) |
MX (1) | MXPA02003312A (es) |
PE (1) | PE20010627A1 (es) |
WO (1) | WO2001022967A1 (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04001026A (es) * | 2001-07-31 | 2005-06-20 | Wyeth Corp | Formulacion de sucralosa para disimular sabores desagradables. |
US7138133B2 (en) * | 2001-10-10 | 2006-11-21 | The Procter & Gamble Company | Orally administered liquid compositions |
US20050249802A1 (en) * | 2004-05-06 | 2005-11-10 | The Procter & Gamble Company | Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients |
TWI489984B (zh) * | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
JP6076962B2 (ja) * | 2011-04-01 | 2017-02-08 | フロリダ大学 リサーチファウンデーション インコーポレイティッド | 治療薬を局所送達するための感熱性を有する粘膜付着性または皮膚粘着性の浸透促進剤 |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
CA2872975A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
AU2013257742A1 (en) | 2012-05-07 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
SG11201407318UA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
SG11201407322QA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
JP2015518855A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 粘膜炎の治療のための組成物および方法 |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
CA2873096A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
SG11201407325YA (en) | 2012-09-08 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammation and lipid disorders |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
CA2914461A1 (en) | 2013-06-04 | 2014-12-11 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
WO2016110865A1 (en) | 2015-01-06 | 2016-07-14 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
CN107207403A (zh) | 2014-09-29 | 2017-09-26 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的组合物和方法 |
SG11201703369WA (en) | 2014-10-27 | 2017-05-30 | Cellix Bio Private Ltd | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5100898A (en) * | 1990-01-25 | 1992-03-31 | Richardson-Vicks Inc. | Antitussive liquid compositions containing dyclonine |
WO1994013280A1 (en) * | 1992-12-04 | 1994-06-23 | Mayor Pharmaceutical Laboratories, Inc. | Sprayable analgesic composition and method of use |
JP2946015B2 (ja) * | 1994-03-10 | 1999-09-06 | 小林化工株式会社 | 安定な抗ウィルス点滴用注射剤 |
US6461622B2 (en) * | 1994-09-07 | 2002-10-08 | Johnson & Johnson Consumer Companies, Inc. | Topical compositions |
JPH10101581A (ja) * | 1996-09-26 | 1998-04-21 | Taisho Pharmaceut Co Ltd | 塩酸ブロムヘキシンの安定化製剤及び安定化方法 |
IT1303684B1 (it) * | 1998-10-30 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di apomorfina in soluzione stabili nel tempo. |
-
2000
- 2000-09-26 HU HU0202797A patent/HUP0202797A3/hu unknown
- 2000-09-26 MX MXPA02003312A patent/MXPA02003312A/es active IP Right Grant
- 2000-09-26 CZ CZ2002947A patent/CZ2002947A3/cs unknown
- 2000-09-26 AU AU79865/00A patent/AU770376B2/en not_active Ceased
- 2000-09-26 JP JP2001526179A patent/JP2003510279A/ja active Pending
- 2000-09-26 BR BR0014441-0A patent/BR0014441A/pt not_active Application Discontinuation
- 2000-09-26 CA CA002385990A patent/CA2385990A1/en not_active Abandoned
- 2000-09-26 EP EP00970493A patent/EP1216044A1/en not_active Ceased
- 2000-09-26 CN CNB008134960A patent/CN1211085C/zh not_active Expired - Fee Related
- 2000-09-26 WO PCT/US2000/026402 patent/WO2001022967A1/en active IP Right Grant
- 2000-09-29 CO CO00074286A patent/CO5210868A1/es not_active Application Discontinuation
- 2000-09-29 PE PE2000001034A patent/PE20010627A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR0014441A (pt) | 2002-06-11 |
CN1211085C (zh) | 2005-07-20 |
CN1376065A (zh) | 2002-10-23 |
EP1216044A1 (en) | 2002-06-26 |
AU7986500A (en) | 2001-04-30 |
CA2385990A1 (en) | 2001-04-05 |
WO2001022967A1 (en) | 2001-04-05 |
MXPA02003312A (es) | 2002-10-04 |
HUP0202797A3 (en) | 2004-05-28 |
JP2003510279A (ja) | 2003-03-18 |
CZ2002947A3 (cs) | 2002-08-14 |
CO5210868A1 (es) | 2002-10-30 |
AU770376B2 (en) | 2004-02-19 |
HUP0202797A2 (hu) | 2003-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20010627A1 (es) | Composiciones que tienen estabilidad mejorada | |
PE20001415A1 (es) | Composiciones que tienen suministro mejorado de activos | |
PE20071310A1 (es) | Formulaciones liquidas de fenilefrina | |
PE20080741A1 (es) | Formulaciones parenterales de metilnaltrexona y sus sales | |
JP2005510538A5 (es) | ||
AR092470A1 (es) | Formulaciones acuosas estables de adalimumab | |
BRPI0009249A (pt) | formulação farmacêutica parenteral de equinocandina contendo tensoativos de formação de micela. | |
AR031450A1 (es) | Composiciones orales que tienen caracteristicas esteticas del consumidor mejoradas | |
AR049084A1 (es) | Composiciones de cuidado personal y concentrados para su elaboracion | |
PE20120023A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
TW200603835A (en) | Mild, moisturizing cleansing compositions | |
CY1113933T1 (el) | Σκευασματα κολικου καθαρισμου | |
ES2155043B1 (es) | Composiciones farmaceuticas comprendiendo acido pirimidin-5-il(3r, 5s)-3,5-dihidroxihept-6-enoico o una sal suya, su estabilizacion con sal fosfato tribasico y su preparacion. | |
UY27320A1 (es) | Nuevas composiciones farmacéuticas | |
UY24246A1 (es) | Vehiculos tropicos que contienen acido azelaico solubilizado y estabilizado | |
PE20070437A1 (es) | FORMULACION ACUOSA hFSH | |
CO5231147A1 (es) | Composicion congelante | |
JP2011256125A (ja) | 歯磨剤組成物 | |
AR073793A1 (es) | Formulacion farmaceutica liquida que contiene paracetamol. excipiente liquido | |
BR112016004427B1 (pt) | composição de dentifrício | |
AR041021A1 (es) | Composicion topica | |
ATE554792T1 (de) | Stabiles wachstumshormon-flüssigformulierung | |
PE20001397A1 (es) | Composiciones que tienen estabilidad mejorada | |
BR112017022439B1 (pt) | Composição para higiene bucal e método para evitar um ou mais dentre sinérese, migração de cor e degradação de cor em uma composição para higiene bucal | |
AR003893A1 (es) | Composicion cosmetica transparente en barra con 2-metil-1,3-propanodiol. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |